Novartis Gains CHMP Positive Opinion for Cosentyx in Adolescent Hidradenitis Suppurativa
Novartis's Cosentyx receives CHMP positive opinion for adolescent HS, triggering label expansion obligations across batch release, packaging, and pharmacovigilance in Europe.


A CHMP positive opinion for Novartis's Cosentyx (secukinumab) in adolescent hidradenitis suppurativa signals an imminent label expansion that will trigger fresh obligations across batch release, packaging configuration, and post-marketing surveillance for European market authorisation holders. If the European Commission ratifies the opinion on its standard timeline, Cosentyx would become the first innovative biologic approved for this indication in patients under 18 in Europe.
Hidradenitis suppurativa is a chronic, systemic, progressive inflammatory skin disease associated with severe pain and significant quality-of-life burden. Extending a biologic label into an adolescent population introduces regulatory requirements that differ materially from the adult authorisation. Under ICH E11 and EMA pediatric regulations, manufacturers must demonstrate age-appropriate formulation and dosing, which for an injectable biologic typically means revisiting device design, labelling, and patient information leaflets to meet readability standards for younger populations and caregivers.
For QA and regulatory leads managing the Cosentyx supply chain, the compliance read centres on batch release documentation. Adolescent-specific presentations, whether a distinct device format or a weight-based dosing schedule, require updated batch records and, where packaging changes, fresh artwork control procedures aligned with Annex 11 and serialisation requirements under the Falsified Medicines Directive. Any change to the summary of product characteristics also triggers a Type II variation workflow, with associated stability data packages.
Post-marketing surveillance obligations expand in parallel. EMA's pediatric post-authorisation safety study requirements, typically embedded in the risk management plan, will require Novartis to generate real-world safety and efficacy data in the adolescent cohort within defined timelines. For pharmacovigilance teams, this means protocol development, registry integration, and periodic safety update report amendments before the first adolescent patient is dosed commercially.
The Commission decision, expected within roughly two months of a positive CHMP opinion under standard procedure, will set the formal date from which national competent authorities can begin pricing and reimbursement negotiations, a variable that plant scheduling teams in supply markets such as Germany, France, and Italy will need to factor into demand forecasting for the new indication.
Completion of the European Commission decision and publication of the updated product label will mark the first measurable checkpoint for manufacturers and distributors preparing adolescent-specific inventory and post-marketing study protocols.
Source: Media4Growth via Indian Pharma Post, 15 November 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
IDEAYA Biosciences Secures FDA Type C Alignment on Dual-Track IDE849 Registrational Strategy in Neuroendocrine Carcinomas

Discussion